{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-malignant+Diseases&page=2", "query": { "condition": "Non-malignant Diseases", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-malignant+Diseases&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T04:23:09.383Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01611298", "title": "Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myelogenous Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome", "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Tetanus", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Robert Krance", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "3 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "3 Years to 70 Years" }, "enrollment_count": 7, "start_date": "2008-03", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-07-24T04:23:09.383Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01611298" }, { "nct_id": "NCT00002504", "title": "Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous/Nonmalignant Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Hoag Memorial Hospital Presbyterian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1992-08", "completion_date": "1999-02", "has_results": false, "last_update_posted_date": "2011-05-12", "last_synced_at": "2026-07-24T04:23:09.383Z", "location_count": 5, "location_summary": "Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002504" }, { "nct_id": "NCT04042480", "title": "A Study of SGN-CD228A in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Melanoma", "Pleural Mesothelioma", "HER2 Negative Breast Neoplasms", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "SGN-CD228A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2019-09-03", "completion_date": "2023-03-09", "has_results": false, "last_update_posted_date": "2023-03-23", "last_synced_at": "2026-07-24T04:23:09.383Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04042480" }, { "nct_id": "NCT02890368", "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Mycosis Fungoides", "Melanoma", "Merkel-cell Carcinoma", "Squamous Cell Carcinoma", "Breast Carcinoma", "Human Papillomavirus-Related Malignant Neoplasm", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "TTI-621 Monotherapy", "type": "DRUG" }, { "name": "TTI-621 + PD-1/PD-L1 Inhibitor", "type": "DRUG" }, { "name": "TTI-621 + pegylated interferon-α2a", "type": "DRUG" }, { "name": "TTI-621 + T-Vec", "type": "OTHER" }, { "name": "TTI-621 + radiation", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2016-09", "completion_date": "2020-03-31", "has_results": false, "last_update_posted_date": "2023-04-05", "last_synced_at": "2026-07-24T04:23:09.383Z", "location_count": 7, "location_summary": "Duarte, California • New York, New York • Portland, Oregon + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02890368" }, { "nct_id": "NCT03602079", "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Gene Mutation", "HER-2 Gene Amplification", "HER2 Positive Gastric Cancer", "Salivary Gland Cancer", "Salivary Gland Tumor", "Salivary Gland Carcinoma", "Salivary Gland Neoplasms", "Lung Cancer", "Colo-rectal Cancer", "Rare Diseases", "Solid Tumor", "Recurrent Gastric Cancer", "Recurrent Colon Cancer", "Recurrent Breast Cancer", "Head and Neck Cancer", "Head and Neck Carcinoma", "Bladder Cancer", "Cervical Cancer", "Liver Cancer", "Bile Duct Cancer", "Urologic Cancer", "Pancreatic Cancer", "Prostate Cancer", "Recurrent Prostate Cancer", "Rectal Cancer", "Recurrent Ovarian Carcinoma", "Recurrent Renal Cell Cancer", "Rectal Cancer Stage II", "Rectal Cancer Stage I", "Rectal Cancer Stage III", "Skin Cancer", "Mouth Cancer", "Lip Cancer Stage I", "Tongue Cancer", "Breast Neoplasm Malignant Primary", "Larynx Cancer", "Tonsil Cancer", "Palate Cancer", "Mucoepidermoid Carcinoma", "Primary Peritoneal Carcinoma", "Mucinous Adenocarcinoma Gastric", "Mucinous Breast Cancer Recurrent", "Cholangiocarcinoma" ], "interventions": [ { "name": "A166", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Klus Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-07-16", "completion_date": "2022-01-12", "has_results": false, "last_update_posted_date": "2023-08-03", "last_synced_at": "2026-07-24T04:23:09.383Z", "location_count": 10, "location_summary": "Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03602079" }, { "nct_id": "NCT04356469", "title": "TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemoglobinopathy (Disorder)", "Severe Aplastic Anemia", "Bone Marrow Failure Syndrome" ], "interventions": [ { "name": "Haploidentical Hematopoietic Cell Transplantation", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Johns Hopkins All Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "0 Years to 21 Years" }, "enrollment_count": 17, "start_date": "2020-07-22", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-07-24T04:23:09.383Z", "location_count": 1, "location_summary": "St. Petersburg, Florida", "locations": [ { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04356469" }, { "nct_id": "NCT00514722", "title": "Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplasia", "Acute Lymphoblastic Leukemia", "Chronic Myelogenous Leukemia", "Multiple Myeloma", "Lymphoma, Large-Cell, Diffuse", "Lymphoma, Mantle-Cell", "Lymphoma, T-Cell, Peripheral", "T-NK Cell Lymphoma", "Hodgkin Disease" ], "interventions": [ { "name": "umbilical cord stem cells", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 4, "start_date": "2002-10", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2013-08-14", "last_synced_at": "2026-07-24T04:23:09.383Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00514722" }, { "nct_id": "NCT02359565", "title": "Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Constitutional Mismatch Repair Deficiency Syndrome", "Lynch Syndrome", "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Medulloblastoma", "Refractory Brain Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Ependymoma", "Refractory Medulloblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Conventional Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Tensor Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Weighted Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-enhanced MR Perfusion", "type": "PROCEDURE" }, { "name": "Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Spectroscopic Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 71, "start_date": "2015-06-03", "completion_date": "2027-01-16", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-07-24T04:23:09.383Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02359565" }, { "nct_id": "NCT04851119", "title": "Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Carcinoma", "Endometrial Carcinoma", "Melanoma", "Neuroblastoma", "Ovarian Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Recurrent Desmoid Fibromatosis", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Refractory Desmoid Fibromatosis", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Hepatocellular Carcinoma", "Refractory Malignant Solid Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Solid Pseudopapillary Neoplasm of the Pancreas", "Wilms Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Dual X-ray Absorptiometry", "type": "PROCEDURE" }, { "name": "Tegavivint", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Months to 30 Years" }, "enrollment_count": 147, "start_date": "2021-11-08", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-07-24T04:23:09.383Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04851119" }, { "nct_id": "NCT01355965", "title": "Autologous Redirected RNA Meso-CIR T Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "Autologous T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2011-05", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2017-09-19", "last_synced_at": "2026-07-24T04:23:09.383Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01355965" } ] }